Drug intelligence / Profile preview

REGN846

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

REGN846 is a fully human monoclonal antibody that was developed for the treatment of atopic dermatitis and pruritus associated with moderate-to-severe atopic dermatitis. It was administered intravenously. The drug originated from Regeneron Pharmaceuticals and Sanofi. Its precise mechanism of action has not been publicly defined or disclosed in available sources. Clinical development included phase 1 and phase 1/2 studies in healthy volunteers and patients with refractory moderate-to-severe pruritus due to atopic dermatitis; however, all clinical development was discontinued after early-phase trials[1][3][4][5].

Other names: REGN846REGN-846REGN 846R846R-846R 846SAR302532SAR-302532SAR 302532

Beyond the preview

Go deeper on REGN846.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN846.

Explore the full profile